由 John R. Fischer
, Staff Reporter | September 18, 2019
Radiation enterprise Akesis kicked off the American Society for Radiation Oncology 2019 Annual Meeting with a preview of its Akesis Gemini 360 linear accelerator.
The development of the platform marks Akesis’ entry into the LINAC market. “We believe that radiation medicine is ripe for disruption, and we’re striving to bring the benefits of high-precision radiation treatment to more people around the globe,” said Volker Stieber, chairman of the board, in a statement. “We believe our patented rotational technology, in-line imaging and commitment to value will create a new paradigm in radiation medicine.”
The Gemini 360 system is equipped with patented rotating gamma technology on a ring gantry and includes a conventional 6 MV LINAC head and 120 leaf MLC to provide users with the capability and flexibility of a conventional radiotherapy treatment system. It also provides users with multiple in-line and real-time imaging options.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Another preview shown was that of the Akesis Galaxy RTi, a gamma stereotactic radiosurgery system with continuous 360 degree rotational technology.
A successor to the Akesis Galaxy, the Akesis Galaxy RTi incorporates real-time, in-line CBCT and kV/kV imaging for improved efficiency and confidence in treatment delivery. The platform is built with 30 gamma sources, which lowers the potential cost of ownership and reduces downtime during source replacement. With it, users can perform high-precision SRS or frameless, fractionated stereotactic radiotherapy, and have access to infinite options available to manipulate dose distribution.
Akesis plans to form a platform approach for the Galaxy series in which treatment centers can select models based on their functionalities and the features they require to fulfill objectives. These platforms are expected to be good fits for high-throughput institutions, smaller cancer centers and value-based reimbursement models.
Both are works in progress and not available for sale. Akesis Galaxy recently obtained FDA clearance.